Santhera Pharmaceuticals Holding AG (SWX:SANN)
17.60
+0.30 (1.73%)
May 13, 2026, 5:31 PM CET
SWX:SANN Revenue
In the year 2025, Santhera Pharmaceuticals Holding AG had annual revenue of 77.19M CHF with 97.32% growth. Santhera Pharmaceuticals Holding AG had revenue of 53.17M in the half year ending December 31, 2025, a decrease of -46.55%.
Revenue
77.19M
Revenue Growth
+97.32%
P/S Ratio
3.13
Revenue / Employee
821.12K
Employees
94
Market Cap
241.29M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 77.19M | 38.07M | 97.32% |
| Dec 31, 2024 | 39.12M | -64.30M | -62.17% |
| Dec 31, 2023 | 103.41M | 95.94M | 1,283.84% |
| Dec 31, 2022 | 7.47M | 9.07M | - |
| Dec 31, 2021 | -1.60M | -16.60M | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bachem Holding AG | 695.07M |
| Basilea Pharmaceutica AG | 232.38M |
| Idorsia | 220.58M |
| Newron Pharmaceuticals | 17.81M |
| BioVersys AG | 3.18M |
| Molecular Partners AG | 681.00K |
| Xlife Sciences AG | 275.31K |
| Addex Therapeutics | 173.00K |
Santhera Pharmaceuticals Holding AG News
- 13 days ago - Santhera Pharmaceuticals Holding AG (SPHDF) Full Year 2025 Earnings Call Highlights: Revenue ... - GuruFocus
- 13 days ago - Full Year 2025 Santhera Pharmaceuticals Holding AG Earnings Call Transcript - GuruFocus
- 15 days ago - Santhera Pharmaceuticals Holding AG Earnings Call Transcript: H2 2025 - Transcripts
- 15 days ago - Santhera Pharmaceuticals Full Year Results for the Year Ended 31 December 2025 - GlobeNewsWire
- 16 days ago - Santhera Moves Closer To Earlier Treatment Access For Young DMD Patients In Europe - Nasdaq
- 8 months ago - Santhera Pharmaceuticals Holding AG Earnings Call Transcript: H1 2025 - Transcripts
- 9 months ago - Santhera Enters into Agreement with Ikris Pharma Network for the Distribution of AGAMREE® (Vamorolone) in India - GlobeNewsWire
- 9 months ago - Santhera Secures Agreement with Uniphar for the Distribution of AGAMREE® (Vamorolone) in five GCC (Gulf Cooperation Council) Countries - GlobeNewsWire